Physician profile
Michael R Havens
NPI 1316928955
$3,454.06
in general payments reported to CMS, 2019-2025
35 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.03 · 2020: $120 · 2021: $548 · 2022: $535 · 2023: $476 · 2024: $904 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.61 | 2021-2025 | |
| Novo Nordisk INC | $562.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $478.59 | 2022-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $357.80 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $186.39 | 2019-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $170.58 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $117.65 | 2021-2025 | Otezla, Repatha, Repatha |
| Inspire Medical Systems, INC. | $91.24 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $81.60 | 2022-2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $76.94 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $54.84 | 2022 | |
| Abbott Laboratories | $43.35 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $38.69 | 2023 | |
| Shield Therapeutics INC | $36.49 | 2024 | |
| Glaxosmithkline, LLC. | $36.03 | 2024 | Trelegy Ellipta, Arexvy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $35.95 | 2020-2021 | |
| Electromed, INC. | $32.19 | 2025 | Smartvest |
| Otsuka America Pharmaceutical, INC. | $28.13 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $27.27 | 2025 | Spravato |
| Galderma Laboratories, L.P. | $23.34 | 2024 | Dysport |
| Dexcom, INC. | $23.13 | 2021 | |
| Astellas Pharma US INC | $22.75 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $22.11 | 2025 | Auvelity |
| Baxter Healthcare | $20.72 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Ironwood Pharmaceuticals, INC | $19.62 | 2023 | Linzess |
| Mylan Specialty L.P. | $19.23 | 2019 | |
| Ardelyx, INC. | $17.48 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $16.80 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Medtronic Minimed, INC. | $16.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.90 | 2021 | |
| Sanofi Pasteur INC. | $15.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.76 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.12 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.81 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Havens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.